×
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
NASDAQ:NBIX

Neurocrine Biosciences Stock Forecast, Price & News

$97.48
-0.98 (-1.00%)
(As of 06/30/2022 04:00 PM ET)
Add
Compare
Today's Range
$96.43
$99.03
50-Day Range
$75.79
$99.93
52-Week Range
$71.88
$108.01
Volume
711,919 shs
Average Volume
807,060 shs
Market Capitalization
$9.32 billion
P/E Ratio
135.39
Dividend Yield
N/A
Price Target
$112.21
30 days | 90 days | 365 days | Advanced Chart

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Stock Forecast (MarketRank)

Overall MarketRank

2.32 out of 5 stars

Medical Sector

273rd out of 1,433 stocks

Biological Products, Except Diagnostic Industry

42nd out of 217 stocks

Analyst Opinion: 2.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
Neurocrine Biosciences logo

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Stock News Headlines

Neurocrine Biosciences Inc Q1 Profit Decreases, misses estimates
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
900
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
6/30/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$112.21
High Stock Price Forecast
$154.00
Low Stock Price Forecast
$76.00
Forecasted Upside/Downside
+15.1%
Consensus Rating
Hold
Rating Score (0-4)
2.47058823529412
Research Coverage
17 Analysts

Profitability

Net Income
$89.60 million
Pretax Margin
7.92%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$1.23 per share
Book Value
$14.48 per share

Miscellaneous

Free Float
91,372,000
Market Cap
$9.32 billion
Optionable
Optionable
Beta
0.70














Neurocrine Biosciences Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Neurocrine Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NBIX, but not buy additional shares or sell existing shares.
View analyst ratings for Neurocrine Biosciences
or view top-rated stocks.

What is Neurocrine Biosciences' stock price forecast for 2022?

17 brokers have issued twelve-month price objectives for Neurocrine Biosciences' stock. Their NBIX stock forecasts range from $76.00 to $154.00. On average, they expect Neurocrine Biosciences' stock price to reach $112.21 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences
or view top-rated stocks among Wall Street analysts.

How has Neurocrine Biosciences' stock price performed in 2022?

Neurocrine Biosciences' stock was trading at $85.17 at the beginning of 2022. Since then, NBIX stock has increased by 14.5% and is now trading at $97.48.
View the best growth stocks for 2022 here
.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Neurocrine Biosciences
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Wednesday, May, 4th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by $0.19. The company had revenue of $310.60 million for the quarter, compared to the consensus estimate of $304.07 million. Neurocrine Biosciences had a net margin of 5.91% and a trailing twelve-month return on equity of 5.30%. The business's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.33 EPS.
View Neurocrine Biosciences' earnings history
.

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Square (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $97.48.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $9.32 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.72 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

Neurocrine Biosciences employs 900 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for Neurocrine Biosciences is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at [email protected], or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.